Greenbrae, California — CVS Health reported a strong performance for the fourth quarter, surpassing earnings and revenue expectations while affirming its optimistic financial outlook for 2026. The company’s ongoing turnaround strategy appears to be gaining traction, as reflected by its recent financial results.

Brian Newman, the company’s chief financial officer, acknowledged the challenges faced in 2024 but noted that the current year has set a more positive trajectory. CVS now anticipates full-year earnings of between $7.00 and $7.20 per share, aligning closely with analysts’ predictions of $7.17. Additionally, the company confirmed its revenue forecast for 2026, projecting at least $400 billion.

Newman indicated that the forecast takes into account significant challenges totaling around $20 billion. Approximately half of these headwinds result from CVS’s decision to exit the Affordable Care Act individual exchange market. The remainder relates to adjustments in its retail operations due to reduced prescription prices stemming from recent agreements made with pharmaceutical companies.

CVS has begun accepting discount cards from TrumpRx, a direct-to-consumer program launched by the recent presidential administration, aiming to lower drug costs for patients. The company is working in conjunction with governmental efforts to reduce healthcare expenses and views these initiatives as complementary rather than adversarial.

Looking ahead, CVS expects growth driven by its Aetna insurance division, particularly as its Medicare Advantage segment shows signs of recovery. Despite previous challenges related to rising medical costs, Newman expressed confidence that the company is on a path toward improved margins and increased profitability.

The fourth-quarter results demonstrated a net income of $2.92 billion, or $2.30 per share, significantly up from $1.62 billion, or $1.30 per share, during the same period in the previous year. Total revenue for the quarter reached $105.69 billion, reflecting an 8.2% increase compared to last year.

Newman’s remarks highlighted that all three of CVS’s business units experienced growth during this quarter. The insurance division generated $36.29 billion in revenue, showing a more than 10% increase. Medicare Advantage plans are expected to continue contributing to enhanced margins.

The pharmacy and consumer wellness division posted sales of $37.66 billion, a 12.4% rise year-over-year, driven by increased prescription volumes and new customer acquisitions from Rite Aid. Conversely, challenges such as reimbursement pressure and the entrance of generic drugs into the market played a role in moderating these gains.

CVS’s health services segment, which includes the pharmacy benefits manager Caremark, realized $51.24 billion in revenue, marking a 9% increase. This service is crucial in negotiating drug prices on behalf of insurance clients and managing drug formularies.

Investors reacted positively to the earnings report, recognizing the strategic moves implemented by CEO David Joyner since he assumed the role in late 2024. The company’s stock has surged by approximately 40% over the past year as it continues to refine its operational approaches and exit less profitable markets.

Overall, CVS remains focused on navigating the complexities of the healthcare landscape while aiming for sustainable growth and improved financial metrics. The confirmation of its future guidance combined with robust quarterly results underscores a shift toward stability for this significant player in the pharmacy industry.